Search Results - "Bedenne, L"

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer by Azria, D., Doyen, J., Jarlier, M., Martel-Lafay, I., Hennequin, C., Etienne, P., Vendrely, V., François, E., de La Roche, G., Bouché, O., Mirabel, X., Denis, B., Mineur, L., Berdah, J., Mahé, M., Bécouarn, Y., Dupuis, O., Lledo, G., Seitz, J., Bedenne, L., Gourgou-Bourgade, S., Juzyna, B., Conroy, T., Gérard, J.

“…Outcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The…”
Get full text

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08) by Ruhstaller, T., Thuss-Patience, P., Hayoz, S., Schacher, S., Knorrenschild, J.R., Schnider, A., Plasswilm, L., Budach, W., Eisterer, W., Hawle, H., Mariette, C., Hess, V., Mingrone, W., Montemurro, M., Girschikofsky, M., Schmidt, S.C., Bitzer, M., Bedenne, L., Brauchli, P., Stahl, M.

“…This open-label, phase III trial compared chemoradiation followed by surgery with or without neoadjuvant and adjuvant cetuximab in patients with resectable…”
Get full text

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study by Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouché, O., Bosset, J.F., Aparicio, T., Mineur, L., Azzedine, A., Hammel, P., Butel, J., Stremsdoerfer, N., Maingon, P., Bedenne, L.

“…The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain. One hundred…”
Get full text

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results by Aparicio, T., Bouché, O., Taieb, J., Maillard, E., Kirscher, S., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Paillaud, E., Retornaz, F., François, E., Bedenne, L.

“…Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy (CT) is a standard treatment but…”
Get full text

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02) by Aparicio, T., Lavau-Denes, S., Phelip, J.M., Maillard, E., Jouve, J.L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., Khemissa, F., Lecomte, T., Provençal, J., Breysacher, G., Legoux, J.L., Lepère, C., Charneau, J., Cretin, J., Chone, L., Azzedine, A., Bouché, O., Sobhani, I., Bedenne, L., Mitry, E., Amoyal, P., Auby, D., Bachet, J.B., Baconnier, M., Benoit, R., Berthelet, O., Bidault, A., Bineau, C., Bordes, G., Bouarioua, N., Boucher, E., Boulat, O., Cleau, D., Couzigou, P., Cuillerier, E., Cumin, I., Denis, B., Di Fiore, F., Derias, V., Ezenfis, J., Faroux, R., Gagnaire, A., Gatineau-Sailliant, G., Garcia, B., Genet, D., Gueye, A., Hammel, P., Lagasse, J.P., Landi, B., Lepage, C., Lobry, C., Lombard-Bohas, C., Mabro, M., Mackiewicz, R., Martin, J., Moncoucy, X., Morvan, F., Mozer, M., Pauwels, M., Petit-Laurent, F., Pouderoux, P., Prost, P., Queuniet, A.M., Ramdani, M., Rebischung, C., Rougier, P., Schnee, M., Seitz, J.F., Stefani, L., Taïeb, J., Terrebonne, E., Texereau, P., Thaury, J., Tougeron, D., Weber, A., Ricard, F., Bonnetain, F., Masskouri, F., Choine, C., Guiliani, F., Le Pessec, G., Fattouh, H., Le Provost, N., Girault, C., Schneider, M.

“…Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients. However, data from a geriatric tailored randomized trial about tolerance to and the…”
Get full text

Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone by Robb, W. B., Messager, M., Dahan, L., Mornex, F., Maillard, E., D'Journo, X. B., Triboulet, J.-P., Bedenne, L., Seitz, J.-F., Mariette, C.

“…Background Patterns of disease recurrence in patients with oesophageal cancer following treatment with neoadjuvant chemoradiotherapy and surgery (nCRTS) or…”
Get full text

Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601 by Ferrand, F, Malka, D, Bourredjem, A, Allonier, C, Bouché, O, Louafi, S, Boige, V, Mousseau, M, Raoul, J.L, Bedenne, L, Leduc, B, Deguiral, P, Faron, M, Pignon, J.P, Ducreux, M

“…Abstract Objective To assess the impact of primary tumour resection on overall survival (OS) of patients diagnosed with stage IV colorectal cancer (CRC)…”
Get full text

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) by Ychou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouché, O., Gamelin, E., Ducreux, M., Conroy, T., Seitz, J.-F., Bedenne, L., Kramar, A.

“…Background: This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse. Patients…”
Get full text

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer by Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., Raoul, J.-L., Bouché, O., Douillard, J.-Y., Adenis, A., Etienne, P.-L., Juzyna, B., Bedenne, L., Conroy, T.

“…A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens…”
Get full text

Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial by Boulin, M., Hillon, P., Cercueil, J. P., Bonnetain, F., Dabakuyo, S., Minello, A., Jouve, J. L., Lepage, C., Bardou, M., Wendremaire, M., Guerard, P., Denys, A., Grandvuillemin, A., Chauffert, B., Bedenne, L., Guiu, B.

“…Summary Background A phase I dose‐escalation trial of transarterial chemoembolisation (TACE) with idarubicin‐loaded beads was performed in cirrhotic patients…”
Get full text

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer by Aparicio, T., Bouché, O., Francois, E., Retornaz, F., Barbier, E., Taieb, J., Kirscher, S., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Bedenne, L., Paillaud, E., Zawadi, Mohamed-Ayman, Volet, Julien, Cavaglione, Gérard, Lepere, Céline, Rougier, Philippe, Zaanan, Aziz, Besson, Dominique, Fawzi, Kara Slimane, Adenis, Antoine, Gatineau-Sailliant, Gilles, Brezault, Catherine, Coriat, Romain, Tougeron, David, Hautefeuille, Vincent, Chone, Laurence, Molin, Yann, Seitz, Jean-François, Le Tallec, Véronique Jestin, Ben Abdelghani, Meher, Villing, Anne-Laure, Aouakli, Amar, Sebbagh, Virginie, Bedjaoui, Ahmed, Mitry, Emmanuel, Carola, Elisabeth, Boulat, Olivier, Queuniet, Anne-Marie, Capitain, Olivier, Jouve, Jean-Louis, Baumgaertner, Isabelle, Almaric, Françoise, Bonnetain, Franck, Subtil, Fabien

“…Older patients have frailty characteristics that impair the transposition of treatment results found in younger patients. Predictive factors are needed to help…”
Get full text

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results by Aparicio, T, Bouché, O, Taieb, J, Maillard, E, Kirscher, S, Etienne, P -L, Faroux, R, Khemissa Akouz, F, El Hajbi, F, Locher, C, Rinaldi, Y, Lecomte, T, Lavau-Denes, S, Baconnier, M, Oden-Gangloff, A, Genet, D, Paillaud, E, Retornaz, F, François, E, Bedenne, L

Get full text

Editorial: IDASPHERE phase I trial for chemoembolisation for HCC ‐ authors' reply: a necessary step for treatment optimisation and standardisation by Boulin, M., Bedenne, L., Guiu, B.

Get full text

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial by Methy, N., Bedenne, L., Conroy, T., Bouché, O., Chapet, O., Ducreux, M., Gérard, J.-P., Bonnetain, F.

“…In resectable rectal cancer trials, pathological parameters are early preoperative treatment efficacy measures. Their validation as surrogate end points for…”
Get full text

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study by de Gramont, A, Bosset, J F, Milan, C, Rougier, P, Bouché, O, Etienne, P L, Morvan, F, Louvet, C, Guillot, T, François, E, Bedenne, L

“…This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule…”
Get more information

A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer by Bonnetain, F., Bouché, O., Michel, P., Mariette, C., Conroy, T., Pezet, D., Roullet, B., Seitz, J.-F., Paillot, B., Arveux, P., Milan, C., Bedenne, L.

“…Background: The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally…”
Get full text

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials by Collette, S., Bonnetain, F., Paoletti, X., Doffoel, M., Bouché, O., Raoul, J.L., Rougier, P., Masskouri, F., Bedenne, L., Barbare, J.C.

“…The objective of this study was to assess the performance of three staging systems [Okuda, Cancer of the Liver Italian Program (CLIP) and Barcelona Clinic…”
Get full text

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) by Bouché, O., Ychou, M., Burtin, P., Bedenne, L., Ducreux, M., Lebreton, G., Baulieux, J., Nordlinger, B., Martin, C., Seitz, J. F., Tigaud, J. M., Echinard, E., Stremsdoerfer, N., Milan, C., Rougier, P.

“…Background: The aim of this study was to evaluate the efficacy of adjuvant chemotherapy after resection for gastric cancer in a randomized controlled trial…”
Get full text

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402) by Doffoël, M, Bonnetain, F, Bouché, O, Vetter, D, Abergel, A, Fratté, S, Grangé, J.D, Stremsdoerfer, N, Blanchi, A, Bronowicki, J.P, Caroli-Bosc, F.X, Causse, X, Masskouri, F, Rougier, P, Bedenne, L

“…Abstract The FFCD 9402 multicentre phase III trial was designed to compare the effects of the combination of Transarterial Lipiodol Chemoembolisation (TACE)…”
Get full text

LBA-04The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results by Bennouna, J., Etienne, P.-L., Bogart, E., Galais, M.-P., Benabdelghani, M., Francois, E., Michel, P., Dahan, L., Metges, J.-P., Ghiringhelli, F., Conroy, T., Kotecki, N., Bedenne, L., El Hajbi, F., Samalin, E., Piessen, G., Delaine-Clisant, S., Penel, N., Mariette, C., Adenis, A.

Get full text